Independent
Tenure on this board
5.6 yrs
Also a director at
Acadia Pharmaceuticals Inc (ACAD)Pacira Biosciences Inc (PCRX)Mirum Pharmaceuticals Inc (MIRM)
Meeting calendar
EWTX · Annual meeting · Thursday, June 4, 2026
Edgewise Therapeutics Inc
3 nominees · 3 ballot items.
Elect three directors; Ratify KPMG LLP as independent registered public accounting firm for 2026; Advisory (non-binding) vote to approve named executive officers’ compensation.
Market cap
$4.1B
1Y TSR
+193.8%
Board grade
B-
Record date
Apr 9, 2026
Filing
DEF 14A
Meeting concluded · Jun 4, 2026
Follow how the vote landed and what changed on Edgewise Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElect three Class II directors — Laura Brege, Badreddin Edris, Ph.D., and Jonathan Root, M.D. — to serve until the 2029 annual meeting.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify KPMG LLP as the company’s independent registered public accounting firm for fiscal year ending December 31, 2026.
- 3
Advisory Vote on the Compensation of Our Named Executive Officers
ManagementBoard: FORNon-binding, advisory vote to approve the compensation of the company’s named executive officers as disclosed in the proxy statement (Say-on-Pay).
More detail
This management proposal requests a non-binding, advisory approval (Say-on-Pay) of the compensation paid to the company’s named executive officers as disclosed in the proxy statement, including compensation tables and narrative discussion. Management seeks shareholder input on its executive pay program, which is designed to align management incentives with long-term stockholder value through a mix of base salary, annual bonuses tied to corporate objectives, and long-term equity incentives (options and RSUs) with multi-year vesting. The board recommends approval, arguing the program is competitive and tied to performance, noting 2025 bonuses were paid at 115% of target due to outperformance on clinical and corporate milestones. The vote is advisory and non-binding, but the board and compensation committee will consider the outcome when making future compensation decisions. The proposal raises typical governance considerations about pay-for-performance alignment, the use of equity to retain executives, and the absence of punitive "single-trigger" change-in-control severance; investors may weigh realized pay versus disclosed pay, the disclosed pay ratio, and severance/change-in-control arrangements when evaluating the merits of the proposal.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
5.5 yrs
Independent
Tenure on this board
7.0 yrs
Also a director at
Omada Health Inc (OMDA)Carlsmed Inc (CARL)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLCActivist | 14.4% | 15,518,492 | $489M |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 9.7% | 10,428,437 | $328M |
| 3 | Paradigm Biocapital Advisors LP | 6.8% | 7,365,038 | $232M |
| 4 | BAKER BROS. ADVISORS LP | 6.1% | 6,575,940 | $207M |
| 5 | JANUS HENDERSON GROUP PLC | 5.4% | 5,792,587 | $182M |
| 6 | Novo Holdings A/S | 5.0% | 5,350,000 | $169M |
| 7 | DRIEHAUS CAPITAL MANAGEMENT LLC | 4.2% | 4,477,942 | $141M |
| 8 | Siren, L.L.C. | 4.1% | 4,430,263 | $140M |
| 9 | PERCEPTIVE ADVISORS LLC | 4.1% | 4,423,974 | $139M |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 3,788,161 | $119M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Edgewise Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$4.1B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.6B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.5B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.8B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.6B
Reference
Frequently asked questions
- When is the Edgewise Therapeutics Inc 2026 annual meeting?
- Edgewise Therapeutics Inc (EWTX) holds its 2026 annual shareholder meeting on Thursday, June 4, 2026.
- What is the record date for the Edgewise Therapeutics Inc 2026 meeting?
- The record date for the Edgewise Therapeutics Inc 2026 meeting is Thursday, April 9, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Edgewise Therapeutics Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Edgewise Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Edgewise Therapeutics Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Edgewise Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.